Heather Bresch, CEO of Mylan.

Adam Jeffery | CNBC

Drugmaker Mylan missed Wall Street estimates for quarterly revenue on Tuesday, hurt by restructuring at its Morgantown plant in West Virginia and a stronger dollar, sending its shares down 4.5%.

Revenue from its North America business fell 6% to $922.9 million and missed estimates of $952.43 million, largely due to increased competition.

Total revenue fell 7% to $2.50 billion and missed estimates of $2.69 billion, according to IBES data from Refinitiv.

The company reported a net loss of $25 million, or 5 cents per share, in the first quarter ended March 31, compared with profit of $87.1 million, or 17 cents per share, a year earlier.

Excluding items, the company earned 82 cents per share and beat expectations of 79 cents per share.

Products You May Like

Articles You May Like

BofA turns bullish on a troubled group, but there’s a catch
Money woes? It could be time to dump your financial advisor
How these financial advisors are using social media to grow their business
This investor has found a way to navigate and make money in volatile Latin American stocks
Under Armour said it has no plans to enter athleisure, will focus on growing full-price stores

Leave a Reply

Your email address will not be published. Required fields are marked *